I thought your readers would be interested in a clinical trial currently enrolling for AON. Currently, there are no options for AON treatment other than steroid administration. This debilitating disease burdens patients and families, and according to the National Multiple Sclerosis Society (NMSS), the first presentation of AON may predict the development of multiple sclerosis within 5 to 10 years in approximately 40% of cases.
There is a clinical trial currently enrolling participants called the OCTAGON trial, a Phase IIb clinical trial of glatiramer acetate in AON patients. AON is demyelination or inflammation of the optic nerve, the nerve that sends images from the retina to the brain. AON may cause a variety of symptoms that can vary from person to person, including blurry vision, vision graying/change in color saturation, loss of vision (usually in one eye) and pain in the eye.
The OCTAGON clinical study is a multi-center study to evaluate the effects of glatiramer acetate on the retinal nerve fiber layer (RNFL) in the back of the eye and visual function in people with a recent first episode of AON. The primary objective of the study is to determine whether glatiramer acetate reduces the amount of axonal loss in the optic nerve after a first event of AON. If you are between the ages of 18-45 years and have had your first episode of AON in one eye only you may be eligible to participate in the OCTAGON study. Time is of the essence, and you must be screened within nine days of your first AON event, so contact your doctor right away to see if you are eligible to participate in the study.
Comment Reply
Linda,
I thought your readers would be interested in a clinical trial currently enrolling for AON. Currently, there are no options for AON treatment other than steroid administration. This debilitating disease burdens patients and families, and according to the National Multiple Sclerosis Society (NMSS), the first presentation of AON may predict the development of multiple sclerosis within 5 to 10 years in approximately 40% of cases.
There is a clinical trial currently enrolling participants called the OCTAGON trial, a Phase IIb clinical trial of glatiramer acetate in AON patients. AON is demyelination or inflammation of the optic nerve, the nerve that sends images from the retina to the brain. AON may cause a variety of symptoms that can vary from person to person, including blurry vision, vision graying/change in color saturation, loss of vision (usually in one eye) and pain in the eye.
The OCTAGON clinical study is a multi-center study to evaluate the effects of glatiramer acetate on the retinal nerve fiber layer (RNFL) in the back of the eye and visual function in people with a recent first episode of AON. The primary objective of the study is to determine whether glatiramer acetate reduces the amount of axonal loss in the optic nerve after a first event of AON. If you are between the ages of 18-45 years and have had your first episode of AON in one eye only you may be eligible to participate in the OCTAGON study. Time is of the essence, and you must be screened within nine days of your first AON event, so contact your doctor right away to see if you are eligible to participate in the study.
January 5, 2010 - 7:10amThis Comment
Reply